Comparative Pharmacology
Head-to-head clinical analysis: E E S 200 versus E E S 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E E S 200 versus E E S 400.
E.E.S. 200 vs E.E.S. 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It may also inhibit ribosomal assembly.
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.
400 mg orally every 6 hours as the ethylsuccinate salt. Maximum daily dose 4 g.
Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.
None Documented
None Documented
Approximately 1.5-2 hours in adults with normal renal function; may be prolonged to 5-6 hours in severe renal impairment.
1.5-2.0 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours) but not significantly changed in renal disease.
Primarily hepatic metabolism and biliary excretion; approximately 5-15% of active drug excreted renally, with fecal elimination accounting for the majority of the remaining dose.
Primarily hepatic (biliary) excretion of unchanged drug and metabolites; approximately 2-5% renal excretion of unchanged drug; 5-15% fecal elimination.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic